4th Human Abuse Liability and Abuse-Deterrent Formulations
November 6 - 7, 2017 - Hyatt Regency Bethesda, One Bethesda Metro Center, Bethesda, 20814, United States MD USExL Events
amagnolo@exlpharma.com
Phone:917-258-5158
For the first time, drug overdoses have become the greatest cause of mortality for people under 50 in the United States. The opioid addiction crisis is rising out of control and leading to an increase in political and market pressure on drug companies from regulators, legislators, insurers, physicians, and patient advocacy groups. New FDA final guidelines for branded opioids were released at the beginning of 2017, and the final guidelines for generics are expected by the end of the year. How you prepare for and respond to them will shape the future of your company’s regulatory compliance and market success. ExL’s 4th Human Abuse Liability and Abuse-Deterrent Formulations conference is the largest industry event specifically focused on the full spectrum of challenges and goals required to create and market drugs with lowered abuse potential. No other event goes into as much detail about preclinical development of abuse-deterrent drugs and delivery mechanisms, clinical trial design, and building strong, reliable networks with every stakeholder throughout the regulatory and market access community.